ArticleBMJ open2016

Benefit-risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experiment.

Tanatape Wanishayakorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.